BEAM
BEAM
NASDAQ · Biotechnology

Beam Therapeutics Inc

$25.91
+0.39 (+1.53%)
As of Aug 8, 1:32 AM ET ·
Financial Highlights (FY 2026)
Revenue
155.45M
Net Income
-88,987,962
Gross Margin
Profit Margin
-57.2%
Rev Growth
+31.9%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.9% 48.9%
Operating Margin -274.6% -247.1% -6.1% -6.1%
Profit Margin -57.2% -54.4% -9.9% -9.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 155.45M 117.88M 476.44M 432.89M
Gross Profit 233.13M 211.83M
Operating Income -426,829,696 -291,285,051 -29,234,950 -26,348,592
Net Income -88,987,962 -60,728,818 -46,993,180 -41,441,136
Gross Margin 48.9% 48.9%
Operating Margin -274.6% -247.1% -6.1% -6.1%
Profit Margin -57.2% -54.4% -9.9% -9.6%
Rev Growth +31.9% +31.9% -6.6% +15.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 420.07M 396.17M
Total Equity 1.92B 2.06B
D/E Ratio 0.22 0.19
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -402,030,186 -289,603,182 -41,088,618 -32,500,848
Free Cash Flow -33,034,013 -43,893,077